Allopurinol News and Research

RSS
Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Study examines role of urate-lowering therapy on renal function in patients with hyperuricemia

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

Joslin gets NIH grant to study potential treatment for kidney disease in people with diabetes

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout: An Interview with Dr. Lawrence Edwards, Chairman and CEO of GUAES

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Gout, uric acid levels and risk of death: an interview with Professor Austin Stack, Graduate Entry Medical School, University of Limerick

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Mayo researchers find rheumatic condition gout may be due to flare-ups in other joints

Vitamin C and gout: an interview with Prof. Lisa Stamp

Vitamin C and gout: an interview with Prof. Lisa Stamp

Research reveals vitamin C does not reduce urate levels in gout patients

Research reveals vitamin C does not reduce urate levels in gout patients

Allopurinol may improve CV outcomes in kidney disease

Allopurinol may improve CV outcomes in kidney disease

Two-part ACR guidelines on gout

Two-part ACR guidelines on gout

Cherry intake reduces risk of gout attacks

Cherry intake reduces risk of gout attacks

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Favorable results from BioCryst’s ulodesine plus allopurinol Phase 2b trial on gout

Steroids may slow progression of life-threatening skin reactions

Steroids may slow progression of life-threatening skin reactions

Risk of gout flare-ups greatly increased by purine rich foods

Risk of gout flare-ups greatly increased by purine rich foods

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

Pharmos completes levotofisopam phase 2a trial on hyperuricemia, gout

BioCryst first quarter revenues increase to $12.2 million

BioCryst first quarter revenues increase to $12.2 million

BioCryst fourth quarter revenues decrease to $5.2 million

BioCryst fourth quarter revenues decrease to $5.2 million

Positive results from BioCryst's BCX4208 Phase 2b study on gout

Positive results from BioCryst's BCX4208 Phase 2b study on gout

Rilonacept appears safe and well-tolerated in patients with gout

Rilonacept appears safe and well-tolerated in patients with gout

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene reports final results from REVLIMID-rituximab combination phase II study for relapsed/refractory CLL

Celgene announces interim results of REVLIMID study on CLL

Celgene announces interim results of REVLIMID study on CLL